Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients

Pharmacotherapy

Volumn 26, Issue 8 I, 2006, Pages 1069-1077

  Lee, Ju Yeun ^a   Hahn, Hyeonjoo ^a   Son, In Ja ^a   Suh, Kyung Suk ^a   Yi, Nam Joon ^a   Oh, Jung Mi ^b   Shin, Wan Gyoon ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Clinical factors; Liver transplantation; Population pharmacokinetics; Tacrolimus

Indexed keywords

BILIRUBIN; CORTICOSTEROID; CYTOCHROME P450 3A4; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NONLINEAR MIXED EFFECT MODEL PROGRAM; NONLINEAR SYSTEM; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SOUTH KOREA; VALIDATION PROCESS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BILIRUBIN; BIOLOGICAL AVAILABILITY; BODY WEIGHT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL NORMALIZED RATIO; LIVER; LIVER TRANSPLANTATION; MALE; MEDICAL RECORDS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; ORGAN SIZE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS;

EID: 33746764453     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.8.1069     Document Type: Review

References (32)

1. European FK506 Multicentre Liver Study Group. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK 506-based immunosuppression. Transplant Proc 1994;26:3260-3.
2. U.S. Multicentre FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporin for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-15.
3. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
4. Backman L, Levy MF, Klintmalm G, for the FK506 Multicenter Study Group. Whole blood and plasma levels of FK506 after liver transplantation: results from the U.S. multicenter trial. Transplant Proc 1995;27:1124.
5. Winkler M, Ringe B, Jost U, et al. Plasma level guided low dose FK506 therapy in patients with early liver dysfunction after liver transplantation. Transplant Proc 1993;25:2688-90.
6. Schwartz M, Holst B, Fackman D, et al, for the U.S. Multicenter FK506 Dose Optimization Study Group. FK506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. Transplant Proc 1995;27:1107.
7. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001;40:283-95.
8. Venkataramanan R, Jain A, Warty V, et al. Pharmacokinetics of FK 506 following oral administration. Transplant Proc 1991;23:931-3.
9. Santomura K, Ozaki N, Okajima H, et al. Pharmacokinetics of FK 506 in living related liver transplantation. Transplant Proc 1996;28:1005.
10. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-90.
11. Ericzon EG, Ekqvist B, Groth CG, Sawe J. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. Transplant Proc 1991;23:2775-6.
12. Lee C, Jusko WJ, Shaefer MS, et al. Pharmacokinetics of tacrolimus (FK-506) in liver transplant patient [abstr]. Clin Pharmacol Ther 1993;53:181A.
13. Jain AB, Abu-Elmagd K, Abdallah H, et al. Pharmacokinetics of FK-506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 1993;33:601-11.
14. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22:447-67.
15. Ette EI, Williams PJ. Population pharmacokinetics. 1. Background, concepts, and models. Ann Pharmacother 2004;38:1702-6.
16. Garcia Sanchez M, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001;40:63-71.
17. Staatz CE, Taylor PJ, Lynch SV, Willis C, Charlene BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 2001;72:1056-61.
18. Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000;50:531-41.
19. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002;72:660-9.
20. Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 2001;28:753-8.
21. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003;9:130-7.
22. Fukatsu S, Yano I, Igarash T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living donor liver transplantation. Eur J Clin Pharmacol 2001;57:479-84.
23. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK 506 assay for the IM analyzer. Transplant Proc 1991;23:2748-9.
24. Abbott Laboratories. IMx and XSYSTEMS for tacrolimus II. Abbott Park, IL; 2005.
25. Beal SL, Sheiner LB, eds. NONMEM user's guide. San Francisco: NONMEM Project Group, University of California; 1992.
26. Williams PJ, Lane JR, Capparelli EV, Kim YH, Coleman R. Direct comparison of three methods for predicting digoxin concentrations. Pharmacotherapy 1996;16:1085-92.
27. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990;22:57-9.
28. Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK 506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991;52:71-7.
29. Kawasaki S, Makuuchi M, Ishizone S, Matsunami H, Terada M, Kawarazaki H. Liver regeneration in recipients and donors after transplantation. Lancet 1991;339:580-1.
30. Tian H, Ou J, Strom Sc, Venkataramanan R. Pharmacokinetics of tacrolimus and mycophenilic acid are altered, but recover at different times during hepatic regeneration in rat. Drug Metab Dispos 2005;33:329-35.
31. Pou L, Brunet M, Andres L, Rodamilans M, Lopez R, Corbella J. Influence of post-transplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int 1998;11:S270-1.
32. Sewing KF. Pharmacokinetics, dosing principles, and blood concentration monitoring of FK 506. Transplant proc 1994;26:3267-9.